GlassScriptPhysician profile
Mindy Thanh Phan
NPI 1063996916
$4,207.90
in general payments reported to CMS, 2019-2025
22 companies · $1,500 in 2025
The $1,500 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.48 · 2022: $87.45 · 2023: $964 · 2024: $1,641 · 2025: $1,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,104.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,414.03 | 2023-2025 | Biktarvy, Epclusa, Descovy |
| Viiv Healthcare Company | $518.12 | 2023-2025 | Cabenuva, Apretude, Dovato |
| Novo Nordisk INC | $469.23 | 2024-2025 | Wegovy |
| Abbvie INC. | $345.03 | 2021-2025 | |
| Dexcom, INC. | $338.33 | 2024-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $232.09 | 2024-2025 | Korlym |
| Paratek Pharmaceuticals, INC. | $172.67 | 2024-2025 | Nuzyra |
| Janssen Pharmaceuticals, INC | $163.57 | 2023-2024 | Xarelto, Spravato |
| Merck Sharp & Dohme LLC | $131.30 | 2024-2025 | Pifeltro, Delstrigo, Isentress |
| Emd Serono, INC. | $81.52 | 2024-2025 | |
| Cumberland Pharmaceuticals, INC. | $61.77 | 2022-2023 | Kristalose |
| Exeltis, USA INC. | $40.99 | 2023 | Slynd |
| Napo Pharmaceuticals INC | $30.78 | 2024 | Mytesi |
| Exact Sciences Corporation | $30.67 | 2024 | Cologuard Collection Kit |
| Ultragenyx Pharmaceutical INC. | $29.20 | 2023 | Crysvita |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $27.46 | 2023 | |
| Csl Behring | $26.16 | 2022 | |
| Glaxosmithkline, LLC. | $22.05 | 2025 | Arexvy, Shingrix |
| Hologic Sales and Service, LLC | $21.87 | 2023 | Aptima |
| Phadia US INC. | $19.87 | 2023 | Immunocap |
| Alkermes, INC. | $17.10 | 2023 | Vivitrol |
| Indivior INC. | $14.09 | 2023 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mindy Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.